Is NCT04920253 recruiting in Bradenton, FL?

Yes, NCT04920253 is currently recruiting participants at its Bradenton, FL location. This diabetic foot ulcer clinical trial is actively enrolling qualified participants.

How do I join the diabetic foot ulcer clinical trial in Bradenton?

To join this clinical trial in Bradenton, complete the eligibility form on this page. A study coordinator will contact you to discuss next steps and determine if you qualify.

Is participation in this Bradenton clinical trial free?

Yes, all study-related care is provided at no cost to qualified participants. Many studies also offer compensation for time and travel expenses.

Diabetic Foot Ulcer Clinical Trial in Bradenton, FL

About This Diabetic Foot Ulcer Study in Bradenton

Prospective, single-blinded, single-center, parallel group, randomized controlled trial (RCT) to assess rate and frequency of wound healing and associated financial savings, when using Medaxis debritom+ versus standard of care as a choice of debridement method, where both arms follow normal wound care practice in use of advanced wound care treatments.

Sponsor: Medaxis, LLC

Who Can Participate

Inclusion Criteria

General Potential subjects are required to meet all of the following criteria for enrollment into the study and subsequent randomization:

At least 18 years old.

The index wound (i.e. current episode of the wound or ulceration) has been present for greater than 4 weeks prior to SV 1 and has had less than 1 year of documented medical treatment, as of the subject's consent for the study participation.

The index wound is a minimum of 1.0 cm2 and a maximum of 25 cm2 at SV1.

Subject understands and is willing to participate in the clinical study and can comply with weekly visits.

Subject must have read and signed the IRB approved Informed Consent Form (ICF) before study specific screening procedures that are not standard of care are undertaken. DFU

Presence of diabetic foot ulcer (DFU) that meets all of the following features:

Wagner Grade 1 or 2 (see Appendix A for definitions), including wounds that extend to the ligament, tendon, joint capsule or fascia

Without abscess or osteomyelitis

The index ulcer will be the largest ulcer if two or more DFUs are present and will be the only one evaluated in the study. If other ulcerations are present on the same foot, they must be more than 2cm distant from index ulcer (edge to edge).

The index ulcer has been offloaded for at least 14 days prior to randomization

Adequate circulation to the affected foot as documented by a Clarifi SFDI Vascular Assessment Tool, or an Ankle Brachial Index (ABI) between 0.7 and 1.3 within 3 months of SV1, using the affected study extremity. As an alternative, arterial Doppler ultrasound can be performed, evaluating for bi-phasic dorsalis pedis and posterior tibial vessels at the level of the ankle within 3 months of SV1 or if monophasic wave forms present must have adequate micro circulation as evidenced by Clarifi SFDI Vascular Assessment Tool. Note: A documented record of an ABI test performed using the index ulcer leg, within 3 months of SV1 is acceptable for the purposes of this study. Otherwise, this must be completed in the Screening Visit. Acceptable alternatives include arterial Doppler ultrasound evaluating vessels at the level of the ankle, or documented adequate microcirculation as determined by a Clarifi SFDI Vascular Assessment Tool. VLU

All wounds using the CEAP VLU Classification, except for those in the

Exclusion Criteria

. (See Appendix A for definitions)

The index ulcer will be the largest ulcer if two or more VLUs are present and will be the only one evaluated in the study. If other Ulcerations are present on the same leg, they must be more than 2cm distant from index ulcer.

All wounds using the Sandy Grading System, except those in the exclusion criteria. (See Appendix A for definitions) Traumatic

All wounds as per the CDC Surgical Wound Classification, with the exception of Class IV or dirty infected wounds, SSI - Deep incisional and organ space. (See Appendix A for definitions) Exclusion Criteria: General Potential subjects meeting any of the following criteria will be excluded from enrollment and subsequent randomization:

The index wound, in the opinion of the investigator, is suspicious for cancer or have a positive carcinoma diagnosis.

Subject has a history of more than two weeks of treatment with immune-suppressants (including systemic corticosteroids \>10mg daily dose), cytotoxic chemotherapy, or application of topical steroids to the wound surface within 1 month prior to first SV1, or who receive such medications during the screening period or who are anticipated to require such medications during the course of the study.

Subject is taking a selective COX-2 inhibitor, such as Celecoxib, for any condition.

Subject is on any investigational drug(s) or therapeutic device(s) within 30 days preceding SV1.

History of radiation at the wound site (regardless of time since last radiation treatment).

Index wound has been previously treated or will need to be treated with any prohibited therapies (See Section 6 of this protocol for a list of prohibited medications and therapies).

Subject has a previous diagnosis of HIV, Hepatitis C, or other contagious diseases.

Presence of any condition(s) which seriously compromises the subject's ability to complete this study or the subject has a known history of poor adherence with medical treatment.

Subject is pregnant or breast-feeding.

Presence of diabetes with poor metabolic control as documented with an HbA1c \>12.0 % within 90 days of randomization.

Subject has end-stage renal disease as evidenced by a serum creatinine \> 3.0mg/dL within 6 months of randomization.

PAR experiences a \>30% change between SV1 and SV2 DFU

Wagner 2 wounds that require debridement of bone.

Osteomyelitis or bone infection of the affected foot as verified by x-ray, CAT Scan, or MRI within 30 days prior to randomization (In the event of an ambiguous diagnosis, the Principal Investigator will make the final decision). VLU

Secondary post thrombotic

Venous Obstruction

Venous Obstruction with reflux

Lipodermato sclerosis or atrophic blanche

Osteomyelitis or bone infection of the affected leg as verified by x-ray, CAT Scan, or MRI within 30 days prior to randomization (In the event of an ambiguous diagnosis, the Principal Investigator will make the final decision). Surgical Dehisced

Using the Sandy Grading System for Surgical Wound Dehiscence: Wounds Grade 3 where organs are exposed, and 3a, where the infection is severe as deemed by the Principal Investigator. Traumatic

Using CDC Surgical Wound Classification, exclude

Class IV - dirty infected wounds

SSI - Deep incisional and organ space

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Bradenton?

Yes, this clinical trial (NCT04920253) has an active research site in Bradenton, FL that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Diabetic Foot Ulcer Treatment Options in Bradenton, FL

If you're searching for diabetic foot ulcer treatment options in Bradenton, FL, this clinical trial (NCT04920253) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Bradenton research site is actively enrolling participants for this clinical trial. You'll receive care from experienced diabetic foot ulcer specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all diabetic foot ulcer clinical trials near you to find additional studies recruiting in your area.

Diabetic Foot Ulcer Clinical Trial in Bradenton, FL

Expert Care in Bradenton

IRB Approved

No-Cost Care

Apply for This Bradenton Location

Why Participate?

Simple Process